IDEAYA Biosciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-112.5M | $-98.5M | $-83.3M | $119.2M | $-77.5M | $-72.2M | $-130.3M | $-51.8M |
| Depreciation & Amortization | $700.0K | $688.0K | $700.0K | $700.0K | $700.0K | $600.0K | $571.0K | $600.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $16.7M | $14.5M | $11.8M | $12.2M | $11.9M | $10.2M | $9.5M | $9.2M |
| Net Cash from Operating Activities | $-88.2M | $-75.2M | $-90.5M | $142.2M | $-62.5M | $-60.3M | $-121.7M | $-49.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $866.0K | $967.0K | $333.0K | $42.0K | $663.0K | $1.3M | $1.1M | $457.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-155.9M | $119.0M | $-97.5M | $41.8M | $45.9M | $79.8M | $-197.1M | $-20.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $359.2M | $1.2M | $2.1M | $301.0K | $1.2M | $26.1M | $2.8M | $286.5M |
| Net Change in Cash | $115.1M | $45.0M | $-185.9M | $184.3M | $-15.4M | $45.6M | $-316.0M | $217.2M |
| Free Cash Flow | $-89.1M | $-76.1M | $-90.8M | $142.2M | $-63.1M | $-61.7M | $-122.8M | $-49.7M |